CGON — CG Oncology, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1991792 ·
Last close
$78.94
Market Cap
$7.00B
52W High
$93.95
52W Low
$37.01
ADV30
1,481,862
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 1,604,000 | -1,065,000 | -63,249,000 | -56,891,000 | 1,046,670,000 | 28,247,000 | 55,704,000 |
| Jun 2026 | 1,157,000 | -2,768,000 | -86,401,000 | -79,056,000 | 1,085,655,000 | 19,636,000 | 56,537,000 |
| Mar 2026 | 1,083,000 | -1,879,000 | -66,389,000 | -60,202,000 | 1,135,262,000 | 33,700,000 | 43,483,000 |
| Dec 2025 | 2,322,000 | -748,000 | -48,700,000 | -41,309,000 | 791,592,000 | 32,490,000 | 38,990,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-178,467,000
Investing CF
$-364,877,000
Financing CF
$548,356,000
CapEx
$-876,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-2.72
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$-518,234,000
Inventory
$1,003,000
Receivables
$417,000
ST Investments
$1,008,642,000
EBIT TTM
$-252,619,000
Pretax Income TTM
$-224,375,000
Interest Exp TTM
—
Analysts
13
Yahoo Snapshot (yfinance, live)
Total Revenue
$6,228,000
EBITDA
$-249,663,008
Free Cash Flow
$-113,709,872
Enterprise Value
$4,724,437,504
Total Cash
$1,028,278,016
Total Debt
$8,819,000
Shares Out
88,640,375
Trailing EPS
$-2.76
Book Value
$9.33
ROE
-26.4%
ROA
-17.7%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 4,040,000 | -190,774,000 | -160,995,000 | 791,592,000 | 38,990,000 | 752,602,000 | -132,346,000 |
| Dec 2024 | 1,139,000 | -114,666,000 | -88,039,000 | 754,797,000 | 21,420,000 | 733,377,000 | -78,713,000 |
| Dec 2023 | 204,000 | -55,449,000 | -48,607,000 | 199,301,000 | 14,511,000 | 184,790,000 | -45,679,000 |
| Dec 2022 | 191,000 | -35,246,000 | -35,443,000 | 147,747,000 | 22,570,000 | 125,177,000 | -29,804,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
$6,228,000
NetIncome TTM
$-224,375,000
OpCashFlow TTM
—
Assets (Latest)
$1,085,655,000
Forward EPS
$-2.92
Max Pain — expiry 2026-12-18
max pain strike: $60.00 · spot: $80.00 · call oi: 3,951 · put oi: 2,228Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| IMVT | Immunovant, Inc. | $6.87B | $33.21 | — |
| IBRX | ImmunityBio, Inc. | $6.66B | $6.26 | — |
| TWST | Twist Bioscience Corp | $7.43B | $112.00 | — |
| KOD | Kodiak Sciences Inc. | $6.33B | $96.80 | — |
| KRYS | Krystal Biotech, Inc. | $8.85B | $298.55 | — |
News headlines (Yahoo Finance, 1h cache)
CG Oncology's Next Stock Rally May Take Time After 'Impressive' Trial Results for Bladder Cancer Drug, RBC Says
2026-11-17 16:00 · Yahoo
Is CG Oncology (CGON) Fully Valued As Phase 3 Trial Success Lifts Its Outlook?
2026-11-17 14:14 · Yahoo
CG Oncology Exceeds Even The 'Most Bullish Conversations;' Shares Break Out
2026-11-16 21:28 · Yahoo
2 Cancer-Drug Developers Seeing Unusual Options Volume
2026-11-16 18:01 · Yahoo
This Biotech Stock Is Up 291% From Its IPO Price. It’s On Pace for a Record Closing High.
2026-11-16 17:37 · Yahoo
CG Oncology drug delivers ‘exceptional’ results in key bladder cancer trial
2026-11-16 17:00 · Yahoo
CG Oncology’s stock up as gene therapy gains second win in NMIBC
2026-11-16 16:03 · Yahoo
CG Oncology Reports 68% Reduction in Bladder Cancer Recurrence Risk in Phase 3 PIVOT-006 Trial
2026-11-16 16:02 · Yahoo
PIVOT-006 Phase 3 Registrational Trial Demonstrates Unprecedented Improvement in Recurrence-Free Survival (RFS) for Intermediate-Risk and High-Grade Ta Non-Muscle Invasive Bladder Cancer (NMIBC)
2026-11-16 13:00 · Yahoo
What CG Oncology (CGON)'s Third Quarter Earnings Means For Shareholders
2026-11-10 13:09 · Yahoo
Recent Insider Activity
| Filed | Trade | Insider | Title | Type | Price | Qty | Value |
|---|---|---|---|---|---|---|---|
| 2026-11-18 16:30:03 | 2026-11-18 | Kalofonos Isabel | Chief Commercial Officer | P - Purchase | 79.76 | 3751 | 299161 |
| 2026-11-18 16:30:07 | 2026-11-18 | Kuan Arthur | CEO | P - Purchase | 78.88 | 30000 | 2366425 |